1. Executive Summary (Confidence: High)

Pureos Bioventures represents the largest institutional Swiss venture capital fund solely dedicated to private biotech companies. Managed by experienced partners from Bellevue Asset Management, the firm closed its first fund, BB Pureos Bioventures LP, in April 2021 with $205 million in committed capital. Pureos distinguishes itself through a team of "career venture capitalists" and former biotech founders who have collectively raised hundreds of millions for clinical development and achieved high-value exits. The firm’s strategy focuses on "Biologicals 2.0"—emerging modalities such as nucleic acids, cell therapies, gene therapies, and next-generation antibody-drug conjugates (ADCs). With a portfolio that has already produced significant M&A activity (e.g., Ipsen's acquisition of ImCheck and Taiho's acquisition of Araris), Pureos has quickly established itself as a premier gatekeeper for European biotech innovation.